Fact CheckerSign in

NCT06410326Completed

Mapping the Longitudinal, Multidimensional Impact of MS in Relation to Variables Indicative of Neurological Reserve

Source: ClinicalTrials.gov · Last updated 13 May 2024

Brief summary (registry, in English)

Some MS patients quickly accumulate neurological deficits, while others remain well for decades. Even though associations with age, sex, health behaviors, comorbidities and social determinants of health are widely acknowledged, the clinical heterogeneity in MS is poorly understood and variables with a robust prognostic value are lacking. Recent data suggest a key role for resilience in the central nervous system, potentially supporting the concept of neurological reserve in MS.

Status (registry)
Completed
Study type
Observational
Enrollment
2600 (actual)
First submitted
4 Apr 2024
Start date
1 Apr 2024
Primary completion date
1 Apr 2024
Lead sponsor
National MS Center Melsbroek
NCT number
NCT06410326

What you commit to

  • Study type: Observational
  • Participants enrolled: 2600
  • From 1 Apr 2024 to the primary completion date, 1 Apr 2024
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • Neuromyelitis Optica diagnosis, AQ4 positive or MOG positive

Who the study is looking for

  • diagnosis of MS needs to be based on diagnostic criteria valid at the time of data entry and confirmed during follow up

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Nationaal Multiple Sclerose Centrum Melsbroek
Coordinator of this site? Confirm its status
MelsbroekBelgiumUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.